SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fanucchi M, Khuri FR. Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 2004; 31: 809-815.
  • 2
    Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006; 24: 2644-2652.
  • 3
    Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10: 1245-1251.
  • 4
    Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 3562-3567.
  • 5
    Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359: 1116-1127.
  • 6
    Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001; 85: 649-655.
  • 7
    Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994; 5: 543-547.
  • 8
    Samlowski WE, Gundacker H, Kuebler JP, et al. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study. Invest New Drugs. 2001; 19: 311-315.
  • 9
    Adjei AA. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. Semin Oncol. 2002; 29( suppl 18): 30-34.
  • 10
    Adjei AA, Erlichman C, Thornton D. Synergistic cytotoxicity of MTA (LY231514) and gemcitabine in vitro and in vivo [abstract]. Paper presented at: 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy; June 16-19, 1998; Amsterdam, the Netherlands. Abstract 644.
  • 11
    Adjei AA, Ehlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000; 18: 11748-11757.
  • 12
    Tonkinson JL, Worzalla JF, Teng C-H, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 1999; 59: 3671-3676.
  • 13
    Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human xenografts. Clin Cancer Res. 2000; 6: 1016-1023.
  • 14
    Hensley ML, Larkin J, Fury M, et al. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clin Cancer Res. 2008; 14: 6310-6316.
  • 15
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 16
    Feinstein TM, Raez LE, Rajasenan KK, et al. Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial—ASCO [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 6069.
  • 17
    Bunn P, Paoletti P, Niyikiza C, et al. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 76a. Abstract 300.
  • 18
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 2636-2644.
  • 19
    Hannah N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-1598.
  • 20
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage nonsmall-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
  • 21
    Ma CX, Nair S, Thomas S, et al. Randomized phase II trial of 3 schedules of pemetrexed and gemcitabine as front-line therapy for advanced nonsmall cell lung cancer. J Clin Oncol. 2005; 23: 5929-5937.